Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma
dc.contributor.author | Rodríguez-Martínez, Carlos E. | |
dc.contributor.author | Sossa-Briceño, Mónica P. | |
dc.contributor.author | Castro-Rodriguez, Jose A. | |
dc.date.accessioned | 2020-08-11T20:19:55Z | |
dc.date.available | 2020-08-11T20:19:55Z | |
dc.date.issued | 2013 | |
dc.description.abstractenglish | Introduction. The choice among the different treatments available can have a great impact on the costs of asthma, Objectives. The objective of this study was to estimate the incremental cost-utility ratio of three inhaled corticosteroids (ICs): budesonide (BUD), fluticasone propionate (FP), and ciclesonide, compared to beclomethasone dipropionate (BDP) (the only IC included in the Compulsory Health Insurance Plan of Colombia), Methods. A Markov-type model was developed to estimate costs and health outcomes of a simulated cohort of patients less than 18 years of age with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from a hospital´s bills and from the national manual of drug prices. The study assumed the perspective of the national healthcare in Colombia. The main outcome was the variable “quality-adjusted life years” (QALY), Results. While treatment with BDP was associated with the lowest cost (£106.16 average cost per patient during 12 months), treatment with FP resulted in the greatest gain in QUALYs (0.9325 QALYs). FP was associated with a greater gain in QALYs compared to BUD and ciclesonide (0.9325 vs. 0.8999 and 0.9051 QALYs, respectively) at lower costs (£231.19 vs. £309.27 and £270.15, respectively), thus leading to dominance. The incremental cost-utility ratio of FP compared to BDP was £19,835.28 per QALY, Conclusions. BDP is the most cost-effective therapy for treating pediatric patients with persistent asthma when willingness to pay (WTP) is less than £21,129.22/QALY, otherwise, FP is the most cost-effective therapy. | eng |
dc.format.mimetype | application/pdf | |
dc.identifier.doi | https://doi.org/10.3109/02770903.2013.767909 | |
dc.identifier.instname | instname:Universidad El Bosque | spa |
dc.identifier.issn | 1532-4303 | |
dc.identifier.reponame | reponame:Repositorio Institucional Universidad El Bosque | spa |
dc.identifier.repourl | https://repositorio.unbosque.edu.co | |
dc.identifier.uri | https://hdl.handle.net/20.500.12495/3762 | |
dc.language.iso | eng | |
dc.publisher | Taylor and Francis | spa |
dc.publisher.journal | Journal of Asthma | spa |
dc.relation.ispartofseries | Journal of Asthma, 1532-4303, Vol. 50, Nro. 4, 2013, p. 410-418 | spa |
dc.relation.uri | https://www.tandfonline.com/doi/full/10.3109/02770903.2013.767909 | |
dc.rights.accessrights | https://purl.org/coar/access_right/c_abf2 | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
dc.rights.accessrights | Acceso abierto | |
dc.rights.creativecommons | 2013-03-05 | |
dc.rights.local | Acceso abierto | spa |
dc.subject.keywords | Asthma | spa |
dc.subject.keywords | Children | spa |
dc.subject.keywords | Cost-effectiveness | spa |
dc.subject.keywords | Developing countries | spa |
dc.subject.keywords | Inhaled corticosteroids | spa |
dc.subject.keywords | Quality adjusted life years | spa |
dc.title | Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma | spa |
dc.title.translated | Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma | spa |
dc.type.coar | https://purl.org/coar/resource_type/c_6501 | |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | |
dc.type.local | Artículo de revista |
Archivos
Bloque original
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- Rodríguez-Martínez, Carlos E..pdf
- Tamaño:
- 668.46 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: